-- Robert Preidt
MONDAY, Oct. 8 (HealthDay News) -- A gene variant linked with a
decreased risk of lung cancer has been identified by
The variant occurs in a gene involved with inflammation and
immune response. The findings add to growing evidence linking
inflammation and immune response with the development of lung
cancer, according to the study authors.
They looked at more than 1,400 variants in inflammation- and
immunity-related genes from 378 lung cancer patients and 450
healthy people. They found that a variant called "rs4648127" in the
NFKB1 gene was associated with a 21 percent to 44 percent reduced
risk of lung cancer.
A protein produced in part from the NFKB1 gene is known to play
an important role in inflammation and immunity by regulating gene
expression, cell death and cell proliferation.
The study was published online Oct. 8 in the journal
"Our study provides further evidence that inflammation may be associated with lung cancer risk," study co-author Meredith Shiels, of the U.S. National Cancer Institute, said in a journal news release.
Further research is needed to learn more about the link between
the NFKB1 gene and lung cancer, she added.
While the study found an association between a gene variant and
lung cancer risk, it did not prove a cause-and-effect
The U.S. Centers for Disease Control and Prevention has more
lung cancer risk factors.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.